Axsome Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The session highlighted a strong CNS focus, rapid organizational growth, and a robust pipeline. AUVELITY's recent ADA approval and label advantages drove a peak sales guidance increase to $8 billion, supported by expanded sales force and payer coverage. Commercial and marketing strategies leverage synergies across indications.
-
Three commercial CNS products drive growth, with Auvelity's Alzheimer's agitation launch imminent and peak sales guidance raised to $8B. Pipeline advances include new phase III studies for smoking cessation and binge eating, while expanded sales force and improved market access are expected to boost revenue in the second half of the year.
-
AUVELITY received new approval for Alzheimer's agitation, driving expanded growth and a raised peak sales forecast. Commercial and pipeline assets are expected to exceed $18 billion in peak sales, with strong financials and a broad CNS pipeline supporting future profitability.
-
FDA approval for a new Alzheimer's agitation treatment with a differentiated safety and efficacy profile is driving a June launch, supported by a major sales force expansion and strong payer access. Growth continues in MDD, migraine, and sleep markets, with a robust pipeline in CNS disorders.
-
AUVELITY's new ADA indication and strong MDD performance are driving a major sales force expansion and broader market access, with robust payer coverage and minimal patient out-of-pocket costs. Growth targets remain ambitious, supported by disciplined DTC investment and a promising pipeline including SYMBRAVO and SUNOSI.
-
Q1 2026 saw 57% revenue growth, FDA approval of AUVELITY for Alzheimer's agitation, and expanded commercial infrastructure. Updated peak sales guidance for AUVELITY is at least $8 billion annually, with strong cash reserves supporting ongoing R&D and launches.
-
FDA approved AUVELITY as the first non-antipsychotic for agitation in Alzheimer's dementia, based on robust efficacy and safety data. Launch is set for June with strong insurance coverage and high anticipated compliance, addressing a major unmet need for millions of patients and caregivers.
-
Strong 2025 sales and operating leverage set the stage for 2026, with a major PDUFA date for Auvelity in Alzheimer's agitation on April 30, 2026. The company is doubling its field force, advancing a robust late-stage pipeline, and expanding market access for key CNS products.
-
Auvelity continues strong growth with expanded sales force and broadening market access, while preparations advance for ADA agitation approval and new indications. Pipeline progress includes new trials for fibromyalgia, epilepsy, and narcolepsy, with multiple late-stage and early-stage programs advancing.
-
AUVELITY continues strong growth with plans to double its sales force and expand indications, including Alzheimer's agitation pending FDA review. The pipeline is robust, with imminent NDA submissions for AXS-12 and ongoing development of Sunosi and AXS-14, targeting large, underserved markets.
-
Auvelity surpassed $500 million in sales, driven by expanded market access and a doubling of the sales force to 600 reps. The pipeline is advancing with an sNDA for Alzheimer's agitation under FDA review, new clinical trials, and strategic in-licensing, while financials approach cash flow positivity.
Fiscal Year 2025
-
Revenue grew 66% year-over-year to $639M, led by Auvelity, Sunosi, and Symbravo. Auvelity surpassed $500M in sales, with strong prescription growth and expanding primary care adoption. Pipeline progress includes a priority review for Auvelity in Alzheimer's agitation and multiple late-stage trials.
-
Awaiting FDA decision for Auvelity in Alzheimer's agitation, with robust clinical data supporting the submission. Commercial expansion is planned for both MDD and ADA, with strong market access and DTC efforts driving prescription growth. Pipeline progress includes multiple late-stage and early-stage programs.
-
Q3 saw strong sales growth across key products, with AUVELITY and SUNOSI leading performance and a successful DTC campaign boosting prescriptions. Regulatory progress continues for ADA and narcolepsy, while financials turned cash flow positive and operating leverage is expected to improve.
-
Q3 2025 saw 63% year-over-year revenue growth to $171M, led by AUVELITY, SUNOSI, and SYMBRAVO. Pipeline progress included a supplemental NDA for AXS-05 in Alzheimer's agitation and multiple late-stage trials. Cash reserves of $325.3M support operations into cash flow positivity.
-
Q2 saw strong commercial growth, with Auvelity and Symbravo launches supported by expanded sales force and coverage. R&D pipeline advanced with key regulatory filings, while feedback on Alzheimer’s agitation program remains positive. Peak sales for new indications are projected to surpass current products.
-
Three commercial products are driving strong revenue growth, with AUVELITY expanding access and SYMBRAVO launching in migraine. The pipeline is robust, with key regulatory filings for AXS-05 in Alzheimer’s agitation and AXS-12 in narcolepsy, and disciplined R&D and commercial strategies support continued momentum.
-
Q2 net sales reached $150 million, driven by Auvelity and Sunosi, with SYMBRAVO newly launched. Regulatory filings for AXS-05 and AXS-12 are on track, and market access for Auvelity expanded by 28 million lives. Growth is expected across all products, with robust clinical data supporting differentiation.
-
Strong Q2 sales and robust cash position support ongoing growth across CNS-focused products. Auvelity's sNDA for Alzheimer's agitation is on track, with significant market potential, while Simbrivo and Sunosi expand through targeted launches and pipeline development.
-
Q2 2025 saw $150M in revenue, up 72% year-over-year, driven by Auvelity and Sunosi growth and the launch of Symbravo. Net loss narrowed to $48M, and major pipeline milestones remain on track, with expanded payer coverage and strong commercial execution expected to drive further growth.
-
The company presented a robust CNS pipeline with late-stage assets in depression, Alzheimer's agitation, ADHD, narcolepsy, fibromyalgia, migraine, and binge eating disorder, supported by strong clinical data and significant commercial potential. Multiple regulatory filings and trial initiations are planned over the next year.
-
Focused on CNS disorders, the company is advancing a diverse pipeline with three commercial products and several late-stage programs targeting major unmet needs. Key regulatory filings, new launches, and robust financials position it for significant growth through 2027.
-
Multiple commercial and late-stage CNS programs are advancing, with imminent launches and regulatory filings planned for migraine, Alzheimer’s agitation, narcolepsy, and fibromyalgia. Growth is driven by expanded sales teams, targeted marketing, and differentiated clinical profiles, with profitability in sight.
-
The conference highlighted a robust CNS pipeline with three commercial products and several late-stage programs, including imminent launches and regulatory milestones. Auvelity and SYMBRAVO are key growth drivers, with strong sales momentum and broad patient applicability.
-
Business remains resilient to macroeconomic risks, with strong AUVELITY growth and a robust pipeline. SYMBRAVO launch and SUNOSI's ADHD and MDD programs are advancing, while Alzheimer's agitation sNDA is on track for 3Q. Cash flow positivity is within reach.
-
Auvelity maintains strong growth with expanded field force and a national DTC campaign planned, aiming for over 80% commercial coverage and steady GTN. Alzheimer's agitation sNDA is on track for Q3, SYMBRAVO migraine launch is set for June, and AXS-12 narcolepsy filing is targeted for the second half.
-
Strong Q1 sales and expanding product launches highlight robust commercial execution, with Auvelity and Symbravo leading growth. Multiple regulatory filings and positive clinical data in CNS indications position the company for continued momentum.
-
Q1 2025 saw 62% revenue growth, driven by Auvelity and Sunosi, and the FDA approval of SYMBRAVO. Multiple late-stage pipeline advances and strong cash reserves position the company for continued growth and upcoming product launches.
-
Strong commercial growth and expanded coverage for Auvelity, with new product launches and clinical milestones ahead. Regulatory progress includes upcoming sNDA for Alzheimer's agitation and new trials in smoking cessation and migraine. Key phase III data readouts are imminent.
-
Strong commercial growth in 2024, with nearly $400M in sales and new product approvals. Multiple NDA submissions and pivotal trial readouts are expected in 2024, including for Alzheimer's agitation, narcolepsy, fibromyalgia, MDD, and ADHD. Commercial and sales force expansions are underway to support launches and label extensions.
-
Symbravo received early FDA approval for acute migraine treatment in adults, demonstrating rapid and sustained efficacy with a favorable safety profile in pivotal trials. The product targets unmet needs in a large, dissatisfied market and is set for commercial launch in four months, with ongoing payer negotiations and plans for future indication expansion.
Fiscal Year 2024
-
Achieved 88% year-over-year revenue growth in 2024, driven by strong Auvelity and Sunosi performance. Preparing for multiple NDA submissions and new product launches in 2025, with a robust cash position to support continued growth.
-
AXS-05 demonstrated robust efficacy in delaying relapse and preventing worsening of agitation in Alzheimer's disease in the ACCORD-2 trial, with consistent safety and tolerability across studies. Three of four pivotal trials were positive, supporting a planned NDA filing in the second half of 2025.
-
Q3 2024 saw record product revenue exceeding $100 million, driven by strong Auvelity and Sunosi growth, with robust pipeline progress and multiple late-stage clinical readouts expected soon. Cash reserves are sufficient to fund operations into profitability.
-
Strong commercial growth and a robust pipeline define the outlook, with pivotal clinical readouts for Alzheimer's agitation and migraine expected by year-end. Auvelity's differentiated profile and AXS-07's regulatory progress position the company for further expansion.
-
The discussion highlighted strong commercial growth for Auvelity, with expanded prescriber reach and payer coverage, and detailed a robust late-stage CNS pipeline. Key catalysts include multiple pivotal trial readouts and NDA filings across migraine, fibromyalgia, Alzheimer's agitation, ADHD, and narcolepsy by year-end.
-
Q2 2024 saw robust revenue growth (87% YoY), led by Auvelity and Sunosi, with expanded payer coverage and strong prescription gains. Multiple late-stage CNS pipeline milestones are expected in the second half of 2024, supporting future growth.
-
The 2024 annual meeting was held virtually, with all proposals—including director elections, auditor ratification, and executive compensation—approved by shareholders. No questions were raised during the Q&A, and forward-looking statements were qualified by standard risk disclosures.
-
Auvelity continues robust growth with expanding first- and second-line use, while the late-stage pipeline targets six marketed indications by 2025. Multiple pivotal trial readouts and NDA submissions are expected in the next 12-18 months, supported by strong financials and IP.